Requirement for CDK6 in MLL-rearranged acute myeloid leukemia

Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1

Barbie, D. A., Tamayo, P., Boehm, J. S., Kim, S. Y., Moody, S. E., Dunn, I. F., Schinzel, A. C., Sandy, P., Meylan, E., Scholl, C., et al. (2009) · Nature · doi:10.1038/nature08460 · Cited by 3,922

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet

Döhner, H., Estey, E. H., Amadori, S., Appelbaum, F. R., Büchner, T., Burnett, A. K., Dombret, H., Fenaux, P., Grimwade, D. J., Larson, R. A., et al. (2009) · Blood · doi:10.1182/blood-2009-07-235358 · Cited by 3,438

Distinct Sets of Genetic Alterations in Melanoma

Curtin, J. A., Fridlyand, J., Kageshita, T., Patel, H. N., Busam, K. J., Kutzner, H., Cho, K.-H., Aiba, S., Bröcker, E.-B., LeBoit, P. E., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050092 · Cited by 2,747

Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials

Grimwade, D. J., Hills, R. K., Moorman, A. V., Walker, H., Chatters, S., Goldstone, A. H., Wheatley, K., Harrison, C. J., & Burnett, A. K. (2010) · Blood · doi:10.1182/blood-2009-11-254441 · Cited by 1,936

RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia

Zuber, J., Shi, J., Wang, E., Rappaport, A. R., Herrmann, H., Sison, E. A., Magoon, D., Qi, J., Blatt, K., Wunderlich, M., et al. (2011) · Nature · doi:10.1038/nature10334 · Cited by 1,870

Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia

Dawson, M. A., Prinjha, R. K., Dittmann, A., Giotopoulos, G., Bantscheff, M., Chan, W.-I., Robson, S. C., Chung, C., Hopf, C., Savitski, M. M., et al. (2011) · Nature · doi:10.1038/nature10509 · Cited by 1,530

Transformation from committed progenitor to leukaemia stem cell initiated by MLL–AF9

Krivtsov, A. V., Twomey, D., Feng, Z., Stubbs, M. C., Wang, Y., Faber, J., Levine, J. E., Wang, J., Hahn, W. C., Gilliland, D. G., et al. (2006) · Nature · doi:10.1038/nature04980 · Cited by 1,513 · cited 1×

A p16 INK4a -Insensitive CDK4 Mutant Targeted by Cytolytic T Lymphocytes in a Human Melanoma

Wölfel, T., Hauer, M., Schneider, J., Serrano, M., Wölfel, C., Klehmann, E., Plaen, E. D., Hankeln, T., Büschenfelde, K. M. Z., & Beach, D. (1995) · Science · doi:10.1126/science.7652577 · Cited by 1,171

Selective Killing of Mixed Lineage Leukemia Cells by a Potent Small-Molecule DOT1L Inhibitor

Daigle, S. R., Olhava, E. J., Therkelsen, C. A., Majer, C. R., Sneeringer, C. J., Song, J. J., Johnston, L. D., Scott, M. P., Smith, J. J., Xiao, Y., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.06.009 · Cited by 926

MLL-Rearranged Leukemia Is Dependent on Aberrant H3K79 Methylation by DOT1L

Bernt, K. M., Zhu, N., Sinha, A. U., Vempati, S., Faber, J., Krivtsov, A. V., Feng, Z., Punt, N., Kedaigle, A. J., Bullinger, L., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.06.010 · Cited by 872

Identification and validation of the dopamine agonist bromocriptine as a novel therapy for high-risk myelodysplastic syndromes and secondary acute myeloid leukemia

Liberante, F. G., Pouryahya, T., McMullin, M., Zhang, S., & Mills, K. (2015) · Oncotarget · doi:10.18632/oncotarget.6773 · Cited by 16

Requirement for LIM kinases in acute myeloid leukemia

Jensen, P., Carlet, M., Schlenk, R. F., Weber, A., Kress, J., Brunner, I., Slabicki, M. M., Grill, G., Weisemann, S., Cheng, Y., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0943-5 · Cited by 16

Enhancing venetoclax activity in hematological malignancies

Satta, T., & Grant, S. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1789588 · Cited by 15

Drug Repurposing for Targeting Acute Leukemia With KMT2A (MLL)—Gene Rearrangements

Tsakaneli, A., & Williams, O. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.741413 · Cited by 16

Targeting Proliferation Signals and the Cell Cycle Machinery in Acute Leukemias: Novel Molecules on the Horizon

di Rorà, A. G. L., Jandoubi, M., Martinelli, G., & Simonetti, G. (2023) · Molecules · doi:10.3390/molecules28031224 · Cited by 16

Targeting the CDK6 Dependence of Ph+ Acute Lymphoblastic Leukemia

Porazzi, P., Dominici, M. D., Salvino, J. M., & Calabretta, B. (2021) · Genes · doi:10.3390/genes12091355 · Cited by 14

Characterization of bone marrow heterogeneity in NK-AML (M4/M5) based on single-cell RNA sequencing

Wu, W., Shi, Z., Tang, Z., Li, H., Huang, X., Liang, X., Li, J., Yao, Y., Zhao, W., Wu, M., et al. (2023) · Experimental Hematology and Oncology · doi:10.1186/s40164-023-00391-5 · Cited by 14

Abemaciclib drives the therapeutic differentiation of acute myeloid leukaemia stem cells

Xie, X., Zhang, W.-J., Zhou, X., Ye, Z.-X., Wang, H., Qiu, Y.-Q., Pan, Y.-T., Hu, Y., Li, L., Chen, Z.-Z., et al. (2023) · British Journal of Haematology · doi:10.1111/bjh.18735 · Cited by 10

Discovery of a potent CDKs/FLT3 PROTAC with enhanced differentiation and proliferation inhibition for AML

Wu, M., Wang, W., Mao, X., Wu, Y., Jin, Y., Liu, T., Lu, Y., Dai, H., Zeng, S., Huang, W., et al. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116539 · Cited by 12

CRISPR Gene Editing of Murine Blood Stem and Progenitor Cells Induces MLL-AF9 Chromosomal Translocation and MLL-AF9 Leukaemogenesis

Sarrou, E., Richmond, L., Carmody, R., Gibson, B., & Keeshan, K. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124266 · Cited by 12

Palbociclib promotes the antitumor activity of Venetoclax plus Azacitidine against acute myeloid leukemia

Wang, A., Fang, M., Jiang, H., Wang, D., Zhang, X., Tang, B., Zhu, X., Hu, W., & Liu, X. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113527 · Cited by 12

Bortezomib suppresses self‐renewal and leukemogenesis of leukemia stem cell by NF‐ĸB‐dependent inhibition of CDK6 in MLL‐rearranged myeloid leukemia

Zhou, B., Qin, Y., Zhou, J., Ruan, J., Xiong, F., Dong, J., Huang, X., Yu, Z., & Gao, S. (2021) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.16377 · Cited by 11

The Identification of APOBEC3G as a Potential Prognostic Biomarker in Acute Myeloid Leukemia and a Possible Drug Target for Crotonoside

Ma, C., Liu, P., Cui, S., Gao, C., Tan, X., Liu, Z., & Xu, R. (2022) · Molecules · doi:10.3390/molecules27185804 · Cited by 10

Inducible MLL-AF9 Expression Drives an AML Program during Human Pluripotent Stem Cell-Derived Hematopoietic Differentiation

Heuts, B. M. H., Arza-Apalategi, S., Alkema, S. G., Tijchon, E. J. H., Jussen, L., Bergevoet, S. M., van der Reijden, B. A., & Martens, J. H. A. (2023) · Cells · doi:10.3390/cells12081195 · Cited by 10

CDK6, a new target in MLL-driven leukemia

Antony‐Debré, I., & Steidl, U. G. (2014) · Blood · doi:10.1182/blood-2014-05-572917 · Cited by 10

A new strategy for exploring the hierarchical structure of cancers by adaptively partitioning functional modules from gene expression network

Xu, J., Jing, R., Liu, Y., Dong, Y., Wen, Z., & Li, M. (2016) · Scientific Reports · doi:10.1038/srep28720 · Cited by 8

A robust approach for the generation of functional hematopoietic progenitor cell lines to model leukemic transformation

Doma, E., Mayer, I. M., Brandstoetter, T., Maurer, B., Grausenburger, R., Menzl, I., Zojer, M., Hoelbl‐Kovacic, A., Carlsson, L., Heller, G., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020003022 · Cited by 9

A C/ebpα isoform specific differentiation program in immortalized myelocytes

García-Cuéllar, M.-P., Akan, S., & Slany, R. K. (2023) · Leukemia · doi:10.1038/s41375-023-01989-8 · Cited by 7

Construction of a microRNA–mRNA Regulatory Network in De Novo Cytogenetically Normal Acute Myeloid Leukemia Patients

Esa, E., Hashim, A. K., Mohamed, E. H. M., Zakaria, Z., Hassan, A. N. A., Yusoff, Y. M., Kamaluddin, N. R., Rahman, A. Z. A., Chang, K. M., Mohamed, R., et al. (2021) · Genetic Testing and Molecular Biomarkers · doi:10.1089/gtmb.2020.0182 · Cited by 7

Drugging Hijacked Kinase Pathways in Pediatric Oncology: Opportunities and Current Scenario

Cândido, M. F., Medeiros, M., Veronez, L. C., Bastos, D., Oliveira, K. L., Pezuk, J. A., Valera, E. T., & Brassesco, M. S. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15020664 · Cited by 8

CDK6 is a regulator of stem cells “Egr” to wake up

Guzmán, M. L. (2015) · Blood · doi:10.1182/blood-2014-11-609230 · Cited by 8

Controlling cell proliferation by targeting cyclin-dependent kinase 6 using drug repurposing approach

Priya, N. M., Balasundaram, A., Kumar, N. S., Kumar, S. U., Kumar, D. T., Magesh, R., Zayed, H., & Doss, C. G. P. (2023) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2023.01.003 · Cited by 6

Narazaciclib, a novel multi-kinase inhibitor with potent activity against CSF1R, FLT3 and CDK6, shows strong anti-AML activity in defined preclinical models

Yang, T., Ke, H., Liu, J., An, X., Xue, J., Ning, J., Feng, H., Xiong, L., Chen, C., Wang, Y., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-59650-y · Cited by 6

Molecular targets for the treatment of AML in the forthcoming 5th World Health Organization Classification of Haematolymphoid Tumours

Molica, M., & Perrone, S. (2022) · Expert Review of Hematology · doi:10.1080/17474086.2022.2140137 · Cited by 6

A Scalable Method for Molecular Network Reconstruction Identifies Properties of Targets and Mutations in Acute Myeloid Leukemia

Ong, E., Szedlak, A., Kang, Y., Smith, P. B., Smith, N. H., McBride, M., Finlay, D., Vuori, K., Mason, J. R., Ball, E. D., et al. (2015) · Journal of Computational Biology · doi:10.1089/cmb.2014.0297 · Cited by 6

Image-based drug screening combined with molecular profiling identifies signatures and drivers of therapy resistance in pediatric AML

Haladik, B., Maurer‐Granofszky, M., Zoescher, P., Heredia, R. J., Frohne, A., Segarra‐Roca, A., Casey, C., Kartnig, F., Giuliani, S., Rashkova, C., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102304 · Cited by 5

MicroRNA-351 Promotes the Proliferation and Invasion of Glioma Cells through Downregulation of NAIF1

Wu, X., Hu, C., Long, C., Zhai, X., Liang, P., & Yu, Z. (2020) · Journal of Molecular Neuroscience · doi:10.1007/s12031-020-01582-z · Cited by 5

An efficient strategy for identifying cancer-related key genes based on graph entropy

Zhang, W., & Wang, S. (2018) · Computational Biology and Chemistry · doi:10.1016/j.compbiolchem.2018.03.022 · Cited by 5

Flavokawain a induces cell cycle arrest through CDT1-dependent p27 regulation and synergizes with venetoclax in acute myeloid leukemia

Jin, L., Jiang, X., Li, Y., Xiang, S., Pei, R., Lu, Y., & Jiang, L. (2025) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2025.117305 · Cited by 4

Dual targeting of CDK6 and LSD1 is synergistic and overcomes differentiation blockade in AML

Brault, L. M., Voisset, E., Desaunay, M., Boudet, A., Kousteridou, P., Letard, S., Carbuccia, N., Goubard, A., Castellano, R., Collette, Y., et al. (2025) · EMBO Molecular Medicine · doi:10.1038/s44321-025-00296-2 · Cited by 4

Targeting cyclin-dependent kinases 4/6 inhibits survival of megakaryoblasts in acute megakaryoblastic leukaemia

Qi, K., Hu, X., Yu, X., Cheng, H., Wang, C., Wang, S., Wang, Y., Li, Y., Cao, J., Pan, B., et al. (2022) · Leukemia Research · doi:10.1016/j.leukres.2022.106920 · Cited by 4

PROTAC-Mediated GSPT1 Degradation Impairs the Expression of Fusion Genes in Acute Myeloid Leukemia

Perzolli, A., Steinebach, C., Krönke, J., Gütschow, M., Zwaan, C. M., Barneh, F., & Heidenreich, O. T. (2025) · Cancers · doi:10.3390/cancers17020211 · Cited by 4

CDK6-Dependent, CDK4-Independent Synovial Hyperplasia in Arthritic Mice and Tumor Necrosis Factor-α-Induced Proliferation of Synovial Fibroblasts

Komatsu, R., Fujii, R., Ogasawara, T., Suzuki‐Takahashi, Y., Chen, S., Sugishita, Y., Niki, H., & Yudoh, K. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26031151 · Cited by 4

Synergistic potential of CDK4 /6 inhibitors and ATRA in non‐ APL AML

Skopek, R., Özcan, S. G., Chmiel, P., Morgner, S., Schütt, J., Zadegan, F. G., Stanko, C., Palusińska, M., Maślińska-Gromadka, K., Sbirkov, Y., et al. (2025) · British Journal of Haematology · doi:10.1111/bjh.70057 · Cited by 3

Transcriptional addiction in mixed lineage leukemia: new avenues for target therapies

Xiao, R., Wang, H., & Liang, K. (2019) · Blood Science · doi:10.1097/bs9.0000000000000011 · Cited by 3

Palbociclib in Acute Leukemias With KMT2A-rearrangement: Results of AMLSG 23-14 Trial

Gaidzik, V. I., Paschka, P., Schlenk, R. F., Weber, D., Fröhling, S., Krämer, A., Wäsch, R., Westermann, J., Mayer, K. T., de Wit, M., et al. (2023) · HemaSphere · doi:10.1097/hs9.0000000000000877 · Cited by 3

An Effective Graph Clustering Method to Identify Cancer Driver Modules

Zhang, W., Zeng, Y., Wang, L., Liu, Y., & Cheng, Y. (2020) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2020.00271 · Cited by 3

GART promotes multiple myeloma malignancy via tumor stemness mediated by activating the HSP90α/CDK6/β-catenin axis

Qian, J., Meng, H., Wang, Z., Sun, Y., Xu, X., Shi, H., Wang, C., Zhou, L., Lv, X., Yang, Y., et al. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177584 · Cited by 2

Discovery of WWZ-11-098: a rigid and selective CDK6 degrader

Zhang, W., Wen, J., Wu, Y., Xuan, Y., Han, Q., Chen, X., Yu, J., Yu, H., & Jiang, B. (2026) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2026.118569 · Cited by 2

CRISPR-based functional genomics for dissecting therapeutic dependency in primary acute myeloid leukemia samples

Cao, Z., Yu, S., Peng, J. J., Barrett, D. R., Liu, Y., Sussman, J., Chen, C., Thadi, A., Liu, L., Alikarami‬, F., et al. (2026) · Molecular Cell · doi:10.1016/j.molcel.2026.02.003 · Cited by 2

A Type II CDK6 Degrader Enables Cellular Targeting beyond the Limits of Type II Inhibition

Kim, J. H., Mills, C. E., Kozicka, Z., Scott, D. C., Jin, C., Jiang, Z., Dwyer, B. G., Geng, Q., Toenjes, S. T., Byun, W. S., et al. (2026) · Journal of the American Chemical Society · doi:10.1021/jacs.6c10277 · Cited by 2

Molekulargenetische Diagnostik - Was wissen die Maschinen? Was wollen wir wissen?

Bauer, P., Hummel, M., Kalle, C. V., Schmutzler, R. K., Block, A., Stroth, M., Woopen, C., & Engelke, K. (2016) · Oncology Research and Treatment · doi:10.1159/000447548 · Cited by 2

Chromosomal Translocations and Gene Rearrangements in Acute Lymphoblastic Leukaemia

Mansour, M. R., & Look, A. T. (2015) · Springer eBooks · doi:10.1007/978-3-319-19983-2_10 · Cited by 1

A cutting-edge approach unravels a novel role for CDK6 in leukemic progenitor cellsPreprint

Doma, E., Mayer, I. M., Brandstoetter, T., Maurer, B., Grausenburger, R., Menzl, I., Zojer, M., Hoelbl‐Kovacic, A., Carlsson, L., Heller, G., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.10.05.325886 · Cited by 1

Nouvelles approches thérapeutiques dans les leucémies aiguës myéloïdes

Bertoli, S., & Récher, C. (2015) · Revue Francophone des Laboratoires · doi:10.1016/s1773-035x(15)30075-7

Role of Cell Cycle Control, Checkpoints and DNA Repair Mechanisms in Stem Cells and Changes with Aging and Cancerogenesis

Brown, A., & Geiger, H. (2017) · Springer eBooks · doi:10.1007/978-3-319-44870-1_87-1

Achillesferse der akuten myeloischen Leukämie entdeckt

Medizin-Verlag, S. (2014) · best practice onkologie · doi:10.1007/s11654-014-0181-2

[The effects of long non-coding RNA AC002454.1 on the biological behaviour of NB4 leukemia cells].

Cao, L., Hu, S., Pan, J., Wang, Y., He, H., Lu, J., Xiao, P., Du, Z., Gu, G., & Chai, Y.-H. (2019) · PubMed Central · doi:10.3760/cma.j.issn.0253-2727.2019.10.014

Faculty Opinions recommendation of A Menin-MLL Inhibitor Induces Specific Chromatin Changes and Eradicates Disease in Models of MLL-Rearranged Leukemia.

Teachey, D. T. (2021) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.737064540.793581830

Role of Cell Cycle Control, Checkpoints, and DNA Repair Mechanisms in Stem Cells and Changes with Aging and Cancerogenesis

Brown, A., & Geiger, H. (2020) · Springer eBooks · doi:10.1007/978-3-319-57415-8_87

HCK maintains the self-renewal of leukaemia stem cells via CDK6 in AMLPreprint

Li, Z., Wang, F., Long, J., Zhang, W., Xu, J., & Liang, A. (2021) · Research Square · doi:10.21203/rs.3.rs-218642/v1

HuR-induced CDK2 translational enhancement aggravates oral tongue squamous carcinomaPreprint

duan, Y., wei, Y., & wang, Y. (2022) · Research Square · doi:10.21203/rs.3.rs-1776427/v1

HuR-induced CDK2 translational enhancement aggravates oral tongue squamous carcinomaPreprint

duan, Y., wei, Y., & wang, Y. (2022) · Research Square · doi:10.21203/rs.3.rs-1776427/v2

Additional file 3 of Characterization of bone marrow heterogeneity in NK-AML (M4/M5) based on single-cell RNA sequencing

Wu, W., Shi, Z., Tang, Z., Li, H., Huang, X., Liang, X., Li, J., Yao, Y., Zhao, W., Wu, M., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22619518

Additional file 4 of Characterization of bone marrow heterogeneity in NK-AML (M4/M5) based on single-cell RNA sequencing

Wu, W., Shi, Z., Tang, Z., Li, H., Huang, X., Liang, X., Li, J., Yao, Y., Zhao, W., Wu, M., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22619521

Additional file 2 of Characterization of bone marrow heterogeneity in NK-AML (M4/M5) based on single-cell RNA sequencing

Wu, W., Shi, Z., Tang, Z., Li, H., Huang, X., Liang, X., Li, J., Yao, Y., Zhao, W., Wu, M., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22619515

Refractory/Relapsed AML in Children and Evolution of Novel Therapies

Juul-Dam, K. L., Ishimaru, S., Ceolin, V., & Zwaan, C. M. (2024) · Pediatric oncology · doi:10.1007/978-3-031-63366-9_14

Diverse epigenomic mechanisms underpin transcriptional dysregulation in Polycomb-altered acute myeloid leukemiaPreprint

Tudose, C., Jones, L., Grosu, T.-I., Fitzgerald, M.-C., Maziak, N., Ling, R. E., Roy, A., Vaquerizas, J. M., Ryan, C. J., & Bond, J. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.08.28.672871

Additional file 6 of HCK maintains the self-renewal of leukaemia stem cells via CDK6 in AML

Li, Z., Wang, F., Tian, X., Long, J., Ling, B., Zhang, W., Xu, J., & Liang, A. (2021) · Figshare · doi:10.6084/m9.figshare.14843152

Additional file 2 of HCK maintains the self-renewal of leukaemia stem cells via CDK6 in AML

Li, Z., Wang, F., Tian, X., Long, J., Ling, B., Zhang, W., Xu, J., & Liang, A. (2021) · Figshare · doi:10.6084/m9.figshare.14843140

Additional file 4 of HCK maintains the self-renewal of leukaemia stem cells via CDK6 in AML

Li, Z., Wang, F., Tian, X., Long, J., Ling, B., Zhang, W., Xu, J., & Liang, A. (2021) · Figshare · doi:10.6084/m9.figshare.14843146

Additional file 1 of HCK maintains the self-renewal of leukaemia stem cells via CDK6 in AML

Li, Z., Wang, F., Tian, X., Long, J., Ling, B., Zhang, W., Xu, J., & Liang, A. (2021) · Figshare · doi:10.6084/m9.figshare.14843137

Additional file 5 of HCK maintains the self-renewal of leukaemia stem cells via CDK6 in AML

Li, Z., Wang, F., Tian, X., Long, J., Ling, B., Zhang, W., Xu, J., & Liang, A. (2021) · Figshare · doi:10.6084/m9.figshare.14843149

Additional file 3 of HCK maintains the self-renewal of leukaemia stem cells via CDK6 in AML

Li, Z., Wang, F., Tian, X., Long, J., Ling, B., Zhang, W., Xu, J., & Liang, A. (2021) · Figshare · doi:10.6084/m9.figshare.14843143

Additional file 7 of HCK maintains the self-renewal of leukaemia stem cells via CDK6 in AML

Li, Z., Wang, F., Tian, X., Long, J., Ling, B., Zhang, W., Xu, J., & Liang, A. (2021) · Figshare · doi:10.6084/m9.figshare.14843155

Additional file 1 of Characterization of bone marrow heterogeneity in NK-AML (M4/M5) based on single-cell RNA sequencing

Wu, W., Shi, Z., Tang, Z., Li, H., Huang, X., Liang, X., Li, J., Yao, Y., Zhao, W., Wu, M., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22619512

Mise en évidence d'un rôle suppresseur de tumeur pour la protéine tyrosine-kinase FES dans le mélanome

Tisserand, J. C. (2016) · theses.fr (ABES) · doi:10.70675/75c7849fz8b54z4676zbd10z2a0e877439d8

La phosphatase CDC25A et le micro-ARN-16 au coeur de la biologie des leucémies aiguës myéloïdes portant une mutation FLT3-ITD

Sueur, G. (2019) · theses.fr (ABES) · doi:10.70675/0ac09b6az69dbz4d1bz93d1zb3ddb8643e57

Ciblage thérapeutique de la protéine CDK6 dans les leucémies aiguës myéloïdes

Brault, L. M. (2022) · theses.fr (ABES) · doi:10.70675/26bca708z5a9az4d80z85bfz9159b330b1e8

CD180 identifies chemoresistant stem-like blasts and reveals a KMT2A-driven vulnerability in acute myeloid leukaemiaPreprint

Eltoukhy, M. M., Winton, A., Masci, F. F., Kania, E., Scott, M. T., Smith, A., Rigby, E., Curran, A., Gouma, A., Cassels, J. E., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.04.23.720316

CDK6 inactivation counteracts CALR‐mutant‐induced MPN evolution and sensitizes MPN stem cells to interferon‐α treatment

Ringhofer, B., Polzer, W., Prchal‐Murphy, M., Doma, E., Kollmann, S., Gamper, E., Kendler, J., Maw, B. S., Zebedin-Brandl, E. M., Li, J., et al. (2026) · HemaSphere · doi:10.1002/hem3.70363

Revisiting retinoic acid in AML therapy: mechanisms of action and rational combination strategies

Özcan, S. G., Stanko, C., Szymański, Ł., Fischer, M., Brioli, A., Zelent, A., & Schenk, T. (2026) · British Journal of Cancer · doi:10.1038/s41416-026-03512-z

MLL fusion-driven activation ofCDK6potentiates proliferation inMLL-rearranged infant ALL

der Linden, M. V., Willekes, M., Roon, E. H. J. V., Seslija, L., Schneider, P., Pieters, R., & Stam, R. W. (2014) · Cell Cycle · doi:10.4161/cc.27757 · Cited by 51

CYC065, potential therapeutic agent for AML and MLL leukaemia

Frame, S., Saladino, C., Davis, S., Blake, D., & Zheleva, D. I. (2015) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2015.04.027 · Cited by 6

Investigation of a Novel Cyclin-Dependent-Kinase (CDK) Inhibitor Cdki-73 As an Effective Treatment Option for MLL-AML

Li, K. L., Bray, S. C. E., Iarossi, D. G., Adams, J., Zhong, L., Noll, B., Rahaman, M. H., Richmond, J., To, L. B., Lewis, I. D., et al. (2015) · Blood · doi:10.1182/blood.v126.23.1365.1365 · Cited by 6

Abstract 3886: Therapeutic potential of CDK inhibitors in MLL leukemias

Frame, S., Hogben, M., Munro, C., Blake, D., Green, S. R., & Zheleva, D. I. (2010) · Cancer Research · doi:10.1158/1538-7445.am10-3886 · Cited by 1

CDK6 Inhibition: A Novel Approach in AML Management

Uras, I. Z., Sexl, V., & Kollmann, K. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21072528 · Cited by 65